Two Las Vegas entrepreneurs attempting to sell the rights to Ebola.com succeeded in selling to the highest bidder -- literally.
Chris Hood and Jon Schultz paid $13,500 for the rights to Ebola.com back in 2008 and have just sold it to a company called Weed Growth Fund.
The terms of sale call for Hood and Schultz to get $50,000 in cash and 19,192 shares of Cannabis Sativa, Inc., a company run by former New Mexico governor Gary Johnson that hopes to market legal cannabis products throughout the world.
The stock is currently trading under the CBDS ticker symbol at $8.55 share, which means the value of the shares sold to Hood and Schultz is $164,091, DomainInvesting.com reports.
Hood said he and Schultz have about 5,000 domain names in their portfolio, including Birdflu.com. He admits the Ebola.com sale got the most public attention, but wasn't the most profitable.
"We've had others like LasVegasRealEstate.com and PaydayLoans.com that sold for more," he told HuffPost. "People don't understand what we do. We don't buy domain names hoping there's a disaster."
As for the future of Ebola.com? It might go to pot, if recent comments made by Johnson on Fox Business are any indication.
Johnson told host Stuart Varney that “we actually believe we have efficacy with regard to treating Ebola," and said it could potentially be a cure.
Johnson subsequently told the Albuquerque Journal, he was not claiming marijuana could cure the Ebola virus, but that more research should be done on whether cannabis compounds might be effective in fighting the disease that has killed nearly 4,500 people, mostly in West Africa.
“If I were on a bed right now, and I was infected by Ebola, anything that might save my life I would take in a nanosecond,” Johnson told the Journal.
Weed Growth Fund CEO Eric Miller said when the new Ebola.com website debuts in a few weeks, it will be a "go-to resource" on all aspects of the disease.
In addition, his company will finance research on cannabis that he says "may or may not prove a connection between cannabis and Ebola prevention."
![]()
Like Us On Facebook |
![]()
Follow Us On Twitter |
![]()
Contact The Author
Chris Hood and Jon Schultz paid $13,500 for the rights to Ebola.com back in 2008 and have just sold it to a company called Weed Growth Fund.
The terms of sale call for Hood and Schultz to get $50,000 in cash and 19,192 shares of Cannabis Sativa, Inc., a company run by former New Mexico governor Gary Johnson that hopes to market legal cannabis products throughout the world.
The stock is currently trading under the CBDS ticker symbol at $8.55 share, which means the value of the shares sold to Hood and Schultz is $164,091, DomainInvesting.com reports.
Hood said he and Schultz have about 5,000 domain names in their portfolio, including Birdflu.com. He admits the Ebola.com sale got the most public attention, but wasn't the most profitable.
"We've had others like LasVegasRealEstate.com and PaydayLoans.com that sold for more," he told HuffPost. "People don't understand what we do. We don't buy domain names hoping there's a disaster."
As for the future of Ebola.com? It might go to pot, if recent comments made by Johnson on Fox Business are any indication.
Johnson told host Stuart Varney that “we actually believe we have efficacy with regard to treating Ebola," and said it could potentially be a cure.
Johnson subsequently told the Albuquerque Journal, he was not claiming marijuana could cure the Ebola virus, but that more research should be done on whether cannabis compounds might be effective in fighting the disease that has killed nearly 4,500 people, mostly in West Africa.
“If I were on a bed right now, and I was infected by Ebola, anything that might save my life I would take in a nanosecond,” Johnson told the Journal.
Weed Growth Fund CEO Eric Miller said when the new Ebola.com website debuts in a few weeks, it will be a "go-to resource" on all aspects of the disease.
In addition, his company will finance research on cannabis that he says "may or may not prove a connection between cannabis and Ebola prevention."
Like Us On Facebook | 
Follow Us On Twitter | 
Contact The Author